Can Fite BiopharmaCANF -1.97%60 PB Ratio is 0.70 as of Jun. 25, 2026, which is 79% below its 10-year median of 3.34. GuruFocus rates CANF with a GF Score™ of 60/100 and a GF Value™ of $5.98 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Can Fite Biopharma ranks better than 89.13% on this metric.
The historical rank and industry rank for Can Fite Biopharma's PB Ratio or its related term are showing as below:
CANF'
s PB Ratio Range Over the Past 10 Years
Min: 0.67 Med: 3.34 Max: 10.89
Current: 0.75
During the past 13 years, Can Fite Biopharma's highest PB Ratio was 10.89. The lowest was 0.67. And the median was 3.34.
CANF's PB Ratio is ranked better than 89.13% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs CANF: 0.75
During the past 12 months, Can Fite Biopharma's average Book Value Per Share Growth Rate was -60.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -49.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -45.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -44.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Can Fite Biopharma was 0.90% per year. The lowest was -55.90% per year. And the median was -38.90% per year.
Back to Basics: PB Ratio
Can Fite Biopharma (AMEX:CANF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Can Fite Biopharma PB Ratio Related Terms
Can Fite Biopharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Can Fite Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Can Fite Biopharma (CANF) has a PB Ratio of 0.70 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Can Fite Biopharma and its competitors. This is 79% below median its historical median of 3.34. Over the past decade, Can Fite Biopharma's PB Ratio has ranged from 0.67 to 10.89. According to the industry distribution chart, Can Fite Biopharma ranks #134 out of 1233 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Can Fite Biopharma's PB Ratio too high?
Can Fite Biopharma's current PB Ratio of 0.70 is 79% below median its 10-year median of 3.34. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 10.89. The Biotechnology industry median PB Ratio is 2.80. Can Fite Biopharma's value of 0.70 is 75% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #134 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #134 out of 1233 companies for PB Ratio. This places Can Fite Biopharma in the top 11% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Can Fite Biopharma's value of 0.70 is 75% below this benchmark. Historically, Can Fite Biopharma's own PB Ratio has ranged from 0.67 to 10.89 over the past decade. While the company's 10-year median is 3.34 vs. the industry median of 2.80, Can Fite Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current PB Ratio of 0.70 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current PB Ratio is 0.70, which is 79% below median its own 10-year median of 3.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.98, compared to a current price of $2.99 — trading 50% below its estimated fair value. The current PB Ratio is 0.70, which is 79% below median its 10-year median of 3.34 and 75% below the Biotechnology industry median of 2.80. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current PB Ratio is 0.70 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
PB Ratio: 0.70 (79% below median its 10-year median of 3.34)
GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
Industry Position: 75% below the Biotechnology median (#134 of 1233)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score
Get the complete analysis for CANF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
